Other endpoints in screening studies for soft tissue sarcomas

Oncologist

Volumn 13, Issue SUPPL. 2, 2008, Pages 27-31

  Verweij, Jaap ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Biomarker; Endpoint; Phase II study; Soft tissue sarcoma

Indexed keywords

BIOLOGICAL MARKER; DACARBAZINE; DOXORUBICIN; GAMMA INTERFERON; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IMATINIB; TOPOTECAN; TRABECTEDIN; ANTINEOPLASTIC AGENT;

BIOASSAY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; DISEASE COURSE; DRUG MEGADOSE; DRUG SCREENING; HUMAN; LOW DRUG DOSE; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA; DIAGNOSTIC IMAGING; METHODOLOGY; PHASE 2 CLINICAL TRIAL; SARCOMA; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; ENDPOINT DETERMINATION; HUMANS; RESEARCH DESIGN; SARCOMA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 47749085982     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.13-S2-27     Document Type: Review

References (23)

1. American Cancer Society. Detailed Guide: Sarcoma - Adult Soft Tissue Cancer. What Are the Key Statistics About Soft Tissue Sarcoma? Available at http://www.cancer.org/docroot/CRI/content/ CRI_2_4_1X_What_are_fhe_key_statistics_for_sarcoma_38.asp?sitearea=.Accessed April 10, 2007.
2. Nielsen OS, Dombernowsky P, Mouridsen H et al. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC Soft Tissue and Bone Sarcoma Group. Br J Cancer 1998;78:1634-1639.
3. Judson I, Radford JA, Harris M et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: A study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001;37:870-877.
4. Lorigan PC, Verweij J, Papai Z et al. Randomized phase III trial of two investigational schedules of ifosfamide versus standard dose doxorubicin in patients with advanced or metastatic soft tissue sarcoma. Proc Am Soc Clin Oncol 2002;21:353a.
5. Nielsen OS, Blay JY, Judson IR et al. Metastatic soft tissue sarcoma in adults: Prognosis and treatment options. Am J Cancer 2003;2:211-221.
6. Le Cesne A, Judson I, Crowther Det al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/ Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000;18:2676-2684.
7. Blay JY, van Glabbeke M, Verweij J et al. Advanced soft-tissue sarcoma: A disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 2003;39:64-69.
8. Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial. J Clin Oncol 2005;23:576-584.
9. Verweij J, van Glabbeke M. Translating targets into treatment: Changes in trial methodology and treatment approaches for soft tissue sarcomas. In: Perry MC, ed. Classification and Treatment of Soft Tissue Sarcomas Educational Book. Alexandria. VA: American Society of Clinical Oncology, 2003;522-530.
10. van Glabbeke M, Verweij J, Judson I et al.; EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002;38:543-549.
11. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
12. Therasse P, Le Cesne A, Van Glabbeke M et al.; EORTC Soft Tissue and Bone Sarcoma Group. RECIST vs. WHO: Prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer 2005;41:1426-1430.
13. Mick R, Crowley JJ, Carroll RJ. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary end point. Control Clin Trials 2000;21:343-359.
14. Zalcberg J, Verweij J, Casali PG et al. Outcome of patients with advanced gastro-intestinal stromal rumors (GIST) crossing over to a daily imatinib dose of 800 mg (HD) after progression on 400 mg (LD) - an international, intergroup study of the EORTC, ISG and AGITG. Eur J Cancer 2005;41:1751-1757.
15. Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): Definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol 2003;54:3-24.
16. Miettinen M. Lasota J. Gastrointestinal stromaltumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1-12.
17. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
18. Lopez-Martin JA, Verweij J, Blay J et al. An exploratory analysis of tumor growth rate (TGR) variations induced by trabectedin (ecteinascidin-743) in patients with pretreated advanced soft tissue sarcoma. Proc Am Soc Clin Oncol 2003;22:819.
19. Izbicka E, Lawrence R. Raymond E et al. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743. NSC-648766) against human tumors explanted from patients. Ann Oncol 1998;9:981-987.
20. van Oosterom AT. Phase II new drug trials in soft tissue sarcomas. In: Pinedo HM, Verweij J, eds. Clinical Management of Soft Tissue Sarcomas. Boston: Martinus Nijhaff, 1986;131-138.
21. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003;21:2237-2246.
22. Cohen MH, Williams GA, Sridhara R et al. FDA drug approval summary: Gefitinib (ZD1839)(Iressa) tablets. The Oncologist 2003;8:303-306.
23. Verweij J, van Oosterom A, Blay JY et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003;39:2006-2011.